Radar · Gene Therapy in California
Best Gene Therapy Companies in California, United States
The 82 best Gene Therapy companies in California, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Kriya Therapeutics.
By Riya SenguptaFinancials
82companies tracked
$3.7Bdisclosed funding
0unicorns
55have raised
Ranked: Best Gene Therapy companies in California
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Kriya Therapeutics Developer of therapeutic solutions for the treatment of diabetes 53Funding top 16%News top 24%Moat top 31%Growth top 43% All 8 signals ▾Fundingtop 16% Newstop 24% Moattop 31% Growthtop 43% Markettop 44% Talenttop 50% Globalbottom 37% Techbottom 32% Funding: Raised $618M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) News: 5 BI events in 12 mo (of 16 tracked, 3 types) · 3 high-value events (IPO/M&A/funding/contracts) in 12 mo rank vs industry peers · Fliar Intelligence Index 53/100 | $618M | 10 mo ago | 159 | Shankar Ramaswamy Co-Founder & CEO | WordPress Site EditorWordPressMySQL+12 | — | — |
| 2 | ReCode Therapeutics Developer of precision medicines for treating lung related diseases 67Funding top 17%Talent top 28%Moat top 31%Market top 42% All 7 signals ▾Fundingtop 17% Talenttop 28% Moattop 31% Markettop 42% Newstop 45% Techtop 48% Globalbottom 39% Funding: Raised $342M across 7 rounds · 7 rounds over 7 yrs (1.0/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 67/100 | $342M | 8 mo ago | 105 | Daniel Siegwart Co-Founder | WordPressApple iCloud MailMicrosoft 365+28 | — | — |
| 3 | Arrowhead Pharmaceuticals Developer of therapeutics to treat multiple diseases | $290M | 12 mo ago | 427 427 → 809 (+89%) | Christopher Anzalone CEO & President | DrupalApple iCloud MailMicrosoft 365+25 | 1,202 patents RNAi therapeutics and targeted antibody/lipid conjugates for disease gene silencing | — |
| 4 | Tenaya Therapeutics Developer of regenerative and gene therapeutics for heart failure | $248M | 16 mo ago | 141 141 → 93 (-34%) | Benoit Bruneau Co-Founder | WordPressDrupalMySQL+24 | 207 patents Engineered AAV gene‑therapy vectors and CRISPR guides for cardiac PLN mutation treatment | — |
| 5 | 4D Molecular Therapeutics Developer of gene therapeutics for genetic disorders | $187M | 72 mo ago | 147 147 → 216 (+47%) | David Kirn Md Co-Founder & CEO | WordPressBugHerdMySQL+23 | 246 patents Patents concentrated in chemistry & materials | — |
| 6 | Senti Bio Developer of cell and gene therapies for patients living with incurable diseases 45Product top 14%Funding top 21%Talent top 22%Tech top 32% All 11 signals ▾Producttop 14% Fundingtop 21% Talenttop 22% Techtop 32% Innovationtop 34% Newsbottom 43% Moatbottom 43% Growthbottom 39% Globalbottom 39% Marketbottom 32% Fin. healthbottom 20% Product: 4 distinct product lines · Company stage: Public Funding: Raised $158M across 8 rounds · 8 rounds over 8 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 45/100 | $158M | 1 mo ago | 122 | Jim Collins Co-Founder | DrupalPHPSalesforce+24 | — | — |
| 7 | AudentesTherapeutics Developer of therapeutics to treat rare genetic diseases | $138M | 128 mo ago | 404 | — | — | — | — |
| 8 | Tocagen Developer of gene therapies for the treatment of cancer | $124M | 105 mo ago | 1 | — | — | 161 patents Gene therapy and CAR‑T delivery vectors with cytosine deaminase prodrug activation | — |
| 9 | Kate Therapeutics Developer of AAV-based gene therapies to treat genetically defined muscle disease | $124M | 25 mo ago | 46 | — | — | — | — |
| 10 | DTx Pharma Provider of RNA-based therapeutics for multiple health purposes | $113M | 63 mo ago | 50 | — | — | — | — |
| 11 | Addition Therapeutics Developer of RNA-mediated genetic medicines 42Funding top 22%Talent top 38%Moat top 42%Market bottom 40% All 5 signals ▾Fundingtop 22% Talenttop 38% Moattop 42% Marketbottom 40% Globalbottom 36% Funding: Raised $106M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 42/100 | $106M | 6 mo ago | — | Kathleen Collins Founder | — | — | — |
| 12 | Ray Therapeutics Developer of therapeutics for degenerative retinal diseases 48Funding top 19%Growth top 35%Tech top 40%Moat top 42% All 7 signals ▾Fundingtop 19% Growthtop 35% Techtop 40% Moattop 42% Talentbottom 49% Globalbottom 39% Marketbottom 28% Funding: Raised $106M across 6 rounds · 6 rounds over 4 yrs (1.5/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 48/100 | $106M | 2 mo ago | 10 | Paul Bresge Co-Founder & CEO | WordPressMySQLMariaDB+21 | — | — |
| 13 | Sangamo BioSciences Developing Zinc finger nuclease based therapeutics for monogenic diseases and HIV | $90M | 87 mo ago | 337 | — | WordPressDrupalApple iCloud Mail+30 | 1,158 patents Patents concentrated in chemistry & materials | — |
| 14 | Spotlight Therapeutics Developer of cancer therapeutics using gene editing | $81M | 33 mo ago | 32 | — | — | — | — |
| 15 | Novome Biotechnologies Developer of gene therapies to treat GI diseases | $77M | 45 mo ago | 44 | Will DeLoache Co-Founder | — | 37 patents Engineered microbial therapeutics and recombinant protein secretion for gut and bile‑acid treatments | — |
| 16 | Switch Therapeutics Developer of therapeutics for neurological disorders | $72M | 39 mo ago | 25 | Dee Datta Co-Founder & CEO | — | — | — |
| 17 | Ceregene Develops AAV-based therapies for neurodegenerative and eye disorders | $72M | 187 mo ago | 30 | Stephen Sherwin Co-Founder | — | 25 patents Gene therapy delivery vectors for retinal and dopaminergic neurodegenerative disease treatment | — |
| 18 | Epicrispr Bio Developer of therapeutics for multiple disease 35Funding top 23%Talent top 38%Moat top 42%Tech bottom 43% All 6 signals ▾Fundingtop 23% Talenttop 38% Moattop 42% Techbottom 43% Globalbottom 37% Marketbottom 32% Funding: Raised $68.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 35/100 | $68M | 14 mo ago | — | Lei Qi Founder | WordPressMySQLPHP+21 | — | — |
| 19 | CODA Biotherapeutics Developer of gene therapy-based analgesics for the treatment of neuropathic pain disorder | $62M | 54 mo ago | 22 | Mitchell H Finer Co-Founder | — | 32 patents Therapeutic peptide/protein compositions targeting neurological disorders. | — |
| 20 | Adverum Biotechnologies Developer of gene therapy based therapies for wet age-related macular degeneration & ophthalmologic disorders | $61M | 28 mo ago | 123 123 → 138 (+12%) | — | WordPressApple iCloud MailMicrosoft 365+21 | 319 patents Gene‑therapy AAV vectors for treating ocular neovascular and inflammatory eye diseases | — |
| 21 | Capsida Developer of next-generation AAV platform for gene therapies | $50M | 61 mo ago | 134 | Nicholas Flytzanis Co-Founder & VP | WordPressMySQLPHP+24 | 64 patents Engineered adeno-associated virus vectors optimized for brain, spinal cord, and heart gene delivery | — |
| 22 | Jasper Therapeutics Developer of therapeutics for chronic diseases by targeting mast cells and stem cells | $49M | 77 mo ago | — | Judith Shizuru Co-Founder | WordPressApple iCloud MailMicrosoft 365+21 | — | — |
| 23 | Creyon Bio Provider of drug design and oligonucleotide-based drug development platform | $40M | 51 mo ago | 38 | Swagatam Mukhopadhyay Chief Scientific Officer & Cofounder & Board Member | WordPressMySQLPHP+15 | — | — |
| 24 | Solstice Biologics Providing solutions for targeting and delivering nucleic acid therapeutics | $40M | 126 mo ago | 4,443 | — | — | 9 patents Modified oligonucleotide synthesis using chiral phosphoramidite auxiliaries for therapeutic nucleic acids | — |
| 25 | Intradigm Corporation Develops RNA interference (RNAi) therapeutics for the treatment of cancer. | $37M | 209 mo ago | 17 | — | — | 136 patents RNAi‑based gene silencing therapeutics for cancer, angiogenesis, and scar‑free wound healing | — |
| 26 | Quark Pharmaceuticals Late stage pharmaceutical company developing RNAi-based therapeutics | $37M | 192 mo ago | 30 | Daniel Zurr Founder & CEO | — | 475 patents Therapeutic nucleic acid agents for preventing ischemia‑reperfusion injury in organs | — |
| 27 | Regulus Therapeutics Innovative medicines company reimagining medicine to improve and extend people’s lives | $35M | 27 mo ago | 30 | — | WordPressMySQLPHP+11 | 403 patents Antisense oligonucleotide therapeutics for polycystic kidney disease and neurological disorders | — |
| 28 | Refuge Biotech Company using CRISPR activation and CRISPR interference to develop novel cancer treatments | $34M | 91 mo ago | 16 | David Parkinson Co-Founder | — | — | — |
| 29 | Modis Therapeutics Provider of therapies for rare genetic diseases | $30M | 92 mo ago | — | Daniel Pietro Co-Founder | — | — | — |
| 30 | Vironexis Biotherapeutics Developer of AAV-delivered T-cell immunotherapies for the treatment of cancer | $26M | 21 mo ago | — | Timothy Cripe Co-Founder | — | 15 patents AAV-based gene therapy vectors targeting metastatic cancer prevention and treatment | — |
| 31 | SomaGenics Developer of RNA-based therapeutics and diagnosis for multiple disease conditions | $26M | 78 mo ago | 5 | — | — | 82 patents Nucleic acid sequencing library prep and RNA‑based therapeutics for gene silencing and wound healing | — |
| 32 | Siren Biotechnology Developer of gene therapies for cancer treatments | $20M | 26 mo ago | 8 | Nicole Paulk Founder & CEO | WordPressMySQLPHP+10 | 15 patents AAV gene therapy vector design, production, and CpG-modified viral manufacturing for oncology | — |
| 33 | Rejuvenate Bio Developer of gene therapies for treating chronic and age-related diseases | $15M | 23 mo ago | 39 | Noah Davidsohn Co-Founder & CSO | Cart FunctionalitySquarespace CommerceSquarespace+12 | — | — |
| 34 | Navega Therapeutics Developer of gene therapy products for chronic pain management | $15M | 13 mo ago | 10 | Prashant Mali Co-Founder | — | — | — |
| 35 | Radar Therapeutics Developer of precision-expressed mRNA-based therapeutics for intractable diseases | $13M | 25 mo ago | — | Eerik Kaseniit Co-Founder | WebflowGSAPjQuery+7 | — | — |
| 36 | ParcelBio Developer of programmable technology to deliver mRNA to diverse cell types in the body | $13M | 4 mo ago | — | Christopher Carlson Co-Founder | — | — | — |
| 37 | Genascence Developer of gene therapies for musculoskeletal and joint diseases | $10M | 49 mo ago | 6 | Thomas Chalberg Founder/CEO | WordPressMySQLPHP+18 | 9 patents Patents concentrated in health & consumer products | — |
| 38 | Arrogene Developer of cancer therapeutics based on a nanotechnological targeting platform | $9M | 79 mo ago | — | Larry Couture Chief Executive Officer | — | 5 patents Polymeric drug delivery systems and antisense glioma therapeutics using polymalic acid. | — |
| 39 | Visgenx Developer of gene therapy for age related muscular degeneration | $9M | 36 mo ago | 9 | Marty Emanuele Co-Founder & CSO | — | 16 patents ELOVL2-based gene therapy vectors for treating ocular diseases | — |
| 40 | Eiger BioPharmaceuticals Developer of antiviral agents against targets in the treatment of hepatitis | $9M | 85 mo ago | 56 | — | — | 181 patents Peptide therapeutics for metabolic disorders and antiviral treatments, especially exendin derivatives. | — |
| 41 | Renova Therapeutics Developer of gene therapies for congestive heart failure and type 2 diabetes | $8M | 23 mo ago | 7 | Jack Reich Chief Executive Officer | WordPressMySQLPHP+17 | — | — |
| 42 | Particella Developer of gene therapies for gastrointestinal diseases | $7M | 50 mo ago | 4 | Timothy Day Co-Founder | — | 3 patents Advanced biologic drug delivery systems and formulations for therapeutic agents | — |
| 43 | Traversa Therapeutics Development and commercialization of RNAi Delivery Technologies | $7M | 206 mo ago | — | — | — | — | — |
| 44 | ImmunoVec Developer of gene therapies for hematopoietic diseases | $4M | 55 mo ago | 6 | Katelyn Masiuk Co-Founder | — | 7 patents Design of enhanced viral vectors for gene therapy and transgene expression | — |
| 45 | Celestial Therapeutics Developer of mRNA-based vaccines and therapies for multiple diseases | $1M | 14 mo ago | — | Leontis Teryazos Co-Founder | — | — | — |
| 46 | Arcturus Therapeutics Developer of RNAi technologies for the treatment of rare orphan diseases | $1M | 32 mo ago | 337 | — | DrupalPHPAmazon Web Services+25 | 488 patents Lipid nanoparticle formulations for RNA/mRNA delivery and vaccine therapeutics | 1 partnership |
| 47 | Eos Neuroscience Developer of treatments for blindness and other neurological conditions | $1M | 165 mo ago | — | Ed Boyden Co-Founder | — | 29 patents Neuro-modulation therapies for chronic pain and ocular gene‑therapy using engineered vectors. | — |
| 48 | Ariz Precision Medicine Developer of RNA therapeutics for cancer | $685K | 70 mo ago | 3 | Lonnie Bookbinder Founder | — | — | — |
| 49 | OncoTelic Developer of RNA therapeutics to treat cancer and infectious diseases | $575K | 6 mo ago | 22 22 → 24 (+9%) | — | WordPressApple iCloud MailMySQL+11 | 6 patents Patents concentrated in health & consumer products | — |
| 50 | Cistern Developer of a platform to build mRNA for therapeutics | $125K | 22 mo ago | — | Hari Bhaskaran Founder | — | — | — |
Top 12 Gene Therapy companies in California
#1
Public · San Francisco, California · founded 2016 · 122 employees$158Mraised▾
Public · San Francisco, California · founded 2016 · 122 employees
Developer of cell and gene therapies for patients living with incurable diseases. The company has developed its proprietary synthetic biology platform to produce cell and gene therapies for cancer treatment. The company's pipeline is comprised of cell therapies engineered with Gene Circuits to target difficult to treat liquid and solid tumors. It offers CAR-NK-based therapies for multiple cancer and tumors.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Product
top 14%Funding
top 21%Talent
top 22%Tech
top 32%Innovation
top 34%News
bottom 43%Product: 4 distinct product lines · Company stage: Public
Funding: Raised $158M across 8 rounds · 8 rounds over 8 yrs (1.0/yr) · Last round Post IPO (May 2026)
Talent: Analyst team rating 5/5 · 3 named leaders on record · 3 C-suite/founder profiles curated
Audience (LinkedIn): 12k LinkedIn followers
Funding rounds
- May 2026Post IPO$40M
- Dec 2024Post IPO$37.6M
- Dec 2024Post IPO$10M
- Jun 2024Grant (prize money)$8M
Founders & team
Investors
Matrix Partners China, Mirae Asset, Ridgeback Capital Management, Lux Capital, Gaingels, KB Investment
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAddthisAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform Launch
#2
Series B · Berkeley, California · founded 2021 · 10 employees$106Mraised▾
Series B · Berkeley, California · founded 2021 · 10 employees
Developer of therapeutics for degenerative retinal diseases. The lead candidate RAY-001 for Retinitis pigmentosa, RAY-002 for geography atrophy, and for other inherited retinal diseases.
Fliar Intelligence Index™ 48how this company ranks against its industry peers
Funding
top 19%Growth
top 35%Tech
top 40%Moat
top 42%Talent
bottom 49%Global
bottom 39%Funding: Raised $106M across 6 rounds · 6 rounds over 4 yrs (1.5/yr) · Last round Series B (Apr 2026)
Growth: Fresh capital in last 24 mo
Tech: 36 technologies across 4/8 capability areas · Cloud: Cloudflare, Fastly · Devops: Nginx, Varnish
Audience (LinkedIn): 8k LinkedIn followers
Funding rounds
- Apr 2026Series B$125M
- Apr 2025Grant (prize money)$8M
- Nov 2023Grant (prize money)$4M
- May 2023Series A$100M
Founders & team
Investors
4Bio Capital, Novo Holdings, Deerfield, MRLV, Platanus, Norwest
Tech stack
CloudflareCloudflare Bot ManagementComplianzCore-JsElementorGenesis Blocks
#3
Series B · Menlo Park, California · founded 2015 · 105 employees$342Mraised▾
Series B · Menlo Park, California · founded 2015 · 105 employees
Developer of precision medicines for treating lung-related diseases. The pipeline includes lead programs which includes RCT1100 an inhaled mRNA-based investigational therapy for primary ciliary dyskinesia caused by mutations in the DNAI1 gene and RCT2100 is an inhaled mRNA-based investigational therapy for cystic fibrosis. It has proprietary non-viral lipid nanoparticle platform that enables the delivery of a variety of payloads, and organ targeting of nucleic acid and protein payloads via both systemic and local delivery.
Fliar Intelligence Index™ 67how this company ranks against its industry peers
Funding
top 17%Talent
top 28%Moat
top 31%Market
top 42%News
top 45%Tech
top 48%Funding: Raised $342M across 7 rounds · 7 rounds over 7 yrs (1.0/yr) · Last round Series B (Sep 2025)
Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 9 curated direct competitors tracked
Funding rounds
- Sep 2025Series B$29M
- Sep 2023Series B$50M
- Jan 2023Series B$10M
- Jun 2022Series B$120M
Founders & team
Investors
Orbimed, Colt Ventures, Vida Ventures, Cystic Fibrosis Foundation, Solasta Ventures, Bioluminescence Ventures
#4
Series D · Redwood City, California · founded 2012 · 159 employees$617.6Mraised▾
Series D · Redwood City, California · founded 2012 · 159 employees
Developer of therapeutic solutions for the treatment of diabetes. The company has developed AAV-based gene therapies for the treatment of type 1 and type 2 diabetes. Its drug candidate KT-A112 contains insulin and glucokinase proteins that help in treating Type 1 & Type 2 diabetes mellitus. It also provides KT-A522 with glucagon-like peptide (GLP-1) receptor agonist for the treatment of Type 2 diabetes, KT-A832 insulin growth factor that helps in treating diabetes mellitus.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Funding
top 16%News
top 24%Moat
top 31%Growth
top 43%Market
top 44%Talent
top 50%Funding: Raised $618M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) · Last round Series D (Jul 2025)
News: 5 BI events in 12 mo (of 16 tracked, 3 types) · 3 high-value events (IPO/M&A/funding/contracts) in 12 mo · Top themes: Funding, Leadership, Capital raise
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Funding rounds
- Jul 2025Series D$320.8M
- May 2022Series C$430M
- Jun 2021Series B$100M
- May 2020Series A$87.6M
Founders & team
Investors
QVT Family Office, Dexcel, Foresite Capital, Narya, Amplo, Asia Alpha
Tech stack
CloudflareGoogle AnalyticsJqueryJquery MigrateModernizrMysql
#5
Series A · San Francisco, California · founded 2021$106.5Mraised▾
Series A · San Francisco, California · founded 2021
Developer of RNA-mediated genetic medicines. The company uses PRINT technology to develop RNA-only therapeutics to transform genetic medicine.
Fliar Intelligence Index™ 42how this company ranks against its industry peers
Funding
top 22%Talent
top 38%Moat
top 42%Market
bottom 40%Global
bottom 36%Funding: Raised $106M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series A (Dec 2025)
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 4/10 · Soonicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 5k LinkedIn followers
Activity (LinkedIn): 1 partnerships (incl. Alliance for mRNA Medicines (AMM)) announced in 12 mo
Funding rounds
- Dec 2025Series A$106.5M
Founders & team
Investors
SR One, Pivotal Life Sciences, Abingworth, Osage University Partners, Gates, BEVC
#6
Acquired · Pasadena, California · founded 1989 · 427 employees$290.2Mraised▾
Acquired · Pasadena, California · founded 1989 · 427 employees
Developer of therapeutics to treat multiple diseases. The company develops medicines that treat intractable diseases by silencing the genes that cause them. The company’s pipeline includes ARO-AAT to treat liver diseases, ARO-APOC3 for Hypertriglyceridemia, ARO-ANG3 for Dyslipidemia, and more.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 101k LinkedIn followers — 2.0% of this cohort's audience
Funding rounds
- May 2025Grant (prize money)$305K
- Dec 2017Post IPO$7.2M
- Jan 2017Post IPO$9.7M
- Sep 2016Post IPO$56.5M
Founders & team
Investors
Silence Therapeutics, Orbimed, RA Capital Management, Perceptive Advisors, RTW Investments, Amgen Business Development
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAkamai
#7
Public · San Francisco, California · founded 2016 · 141 employees$248Mraised▾
Public · San Francisco, California · founded 2016 · 141 employees
Developer of regenerative and gene therapeutics for heart failure. The company's pipeline include MYBPC3 for genetic hypertrophic cardiomyopathy, PKP2 for genetic arrhythmogenic right ventricular cardiomyopathy, DWORF for dilated cardiomyopathy, and HDAV6i for heart failure with preserved ejection fraction.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 19k LinkedIn followers
Funding rounds
- Feb 2025Grant (prize money)$8M
- Mar 2021Series C$106M
- Oct 2019Series B$92M
- Dec 2016Series A$50M
Founders & team
Investors
RTW Investments, RA Capital Management, Fidelity Investments, The Column Group, Casdin Capital, Google Ventures
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAkamaiAmazon Web ServicesBackbone.JsBootstrap
#8
Seed · San Francisco, California · founded 2023$13.2Mraised▾
Seed · San Francisco, California · founded 2023
Developer of programmable technology to deliver mRNA to diverse cell types in the body. The company has proprietary nanoparticle technology, which is ‘STAmP’, stabilizes the mRNA and utilizes an interchangeable, lock-and-key-like targeting mechanism which enables fully customizable mRNA medicines for kidney disorders, chronic liver diseases, and immune system dysregulation.
Funding rounds
- Feb 2026Seed$13.2M
Founders & team
Investors
Breyer Capital, General Catalyst, Y Combinator, Metaplanet, ZAKA, Surgepoint Capital
#9
Series B · San Francisco, California · founded 2018$68Mraised▾
Series B · San Francisco, California · founded 2018
Developer of therapeutics for multiple diseases. It offers gene therapies using ultracompact Cas proteins which modulate gene expression without cutting DNA. The company's platform leverages the power of CRISPR/Cas9 gene editing to target specific genes and achieve therapeutic outcomes. The pipeline includes EPI-321 for facioscapulohumeral muscular dystrophy, EPI-221, EPI-224 for genetic disorder, EPI 114 and EPI 111 for petinas pigmentosa.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Funding
top 23%Talent
top 38%Moat
top 42%Tech
bottom 43%Global
bottom 37%Market
bottom 32%Funding: Raised $68.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series B (Mar 2025)
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 4/10 · Soonicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 7k LinkedIn followers
Funding rounds
- Mar 2025Series B$68M
Founders & team
Investors
Ally Bridge Group, Solve FSHD, LDV Partners
#10
Funding Raised · San Diego, California · founded 2018 · 10 employees$14.5Mraised▾
Funding Raised · San Diego, California · founded 2018 · 10 employees
Developer of gene therapy products for chronic pain management. The company's novel gene therapy platform to target and imitate the patients with a mutation in the genome where no pain is felt., and apply it to treat pain.
Funding rounds
- Apr 2025Grant (prize money)$4.3M
- Apr 2025Grant (prize money)$4.3M
- Apr 2025Grant (prize money)$2.2M
- Sep 2023Grant (prize money)$400K
Founders & team
Investors
HHS
#11
Acquired · San Diego, California · founded 2020 · 46 employees$123.8Mraised▾
Acquired · San Diego, California · founded 2020 · 46 employees
Developer of AAV-based gene therapies to treat genetically defined muscle disease
Funding rounds
- May 2024Series A$21.8M
- Jun 2023Series A$51M
- Aug 2021Series A$35M
- Feb 2021Series A$16M
Investors
Westlake Village Biopartners, Versant Ventures, Osage University Partners, University of Florida
#12
Seed · San Diego, California · founded 2021$26Mraised▾
Seed · San Diego, California · founded 2021
Developer of AAV-delivered T-cell immunotherapies for the treatment of cancer. The company has TransJoin AAV gene therapy platform enables the creation of immunotherapies, including CAR-T for blood-based cancers, solid tumor metastasis prevention, and a cancer vaccine. The company's product include VNX-101, for the treatment of CD19+ acute lymphoblastic leukemia.
Funding rounds
- Sep 2024Seed$26M
Founders & team
Investors
Drive Capital, Future Ventures, Moonshots Capital, Capital Factory
Funding & investor landscape
$3.7Btotal disclosed funding
54companies funded
212disclosed rounds
2rounds last 90 days
Most active investors
Notable founders
Jim Collins
Co-Founder · Senti Bio
Wilson Wong
Co-Founder · Senti Bio
Paul Bresge
Co-Founder & CEO · Ray Therapeutics
Daniel Siegwart
Co-Founder · ReCode Therapeutics
Philip Thomas
Co-Founder · ReCode Therapeutics
Shankar Ramaswamy
Co-Founder & CEO · Kriya Therapeutics
Roger Jeffs
Co-Founder · Kriya Therapeutics
Kathleen Collins
Founder · Addition Therapeutics
Ron Park
CEO · Addition Therapeutics
Christopher Anzalone
CEO & President · Arrowhead Pharmaceuticals
Benoit Bruneau
Co-Founder · Tenaya Therapeutics
Bruce Conklin
Co-Founder · Tenaya Therapeutics
Prism market signals · United States · country-scoped Prism corpus, 11,961,869 docs
Market landscape — 10 sub-themes by coverage
Share of Gene Therapy coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH IN CALIFORNIA · Health & Bio
How research on Gene Therapy in California is moving
A read on the academic research around Gene Therapy in California — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 591 papers.
591 papers · stance +0.61 · 49% breakthrough · 11% concern
top institutions
- University of California, Los Angeles118
- University of California, Berkeley86
- University of California, San Francisco79
- California Institute of Technology58
- University of California, Davis54
leading researchers
David V. Schaffer · Pin Wang · Donald B. Kohn · Mariana Puntel · Meike Visel · Xinhong Chen
prism intelligence · tone & topics
98% positive · 1% critical tone
PharmaceuticalsBiotechnologyMedical ResearchHealthHealthcareClinical Trials
▲
Breakthroughs271 · 46%
▲ 40%→53% share
▲1.3× share momentum8 median citations39% since 2021mostly methods-led
Breakthroughs are rising (40%→53% of field), led by Genome editing.
rising sub-themes (early→recent)
- Genome editing2→17
- CRISPR3→16
- Gene delivery36→48
- Cas92→11
- Capsid1→8
Newly emergingMessenger RNA 0→7 · Cell 0→7 · Gene expression 0→6
Landmark In Vivo–Directed Evolution of a New Adeno-Associated Virus for Therapeutic Outer Retinal Gene Delivery from the Vitreous · 712 cites
◆
Advancements224 · 38%
▼ 44%→30% share
▼0.7× share momentum14 median citations27% since 2021mostly empirical
Advancements are cooling (44%→30% of field), led by Vaccination.
rising sub-themes (early→recent)
- Vaccination1→6
- In vivo4→8
- Genome editing2→5
- CRISPR1→3
- Cytotoxic T cell1→3
Newly emergingAttenuated vaccine 0→3 · Cardiomyopathy 0→3 · Heterologous 0→3
Landmark Viral Vectors for Gene Therapy: Translational and Clinical Outlook · 437 cites
▼
Concerns59 · 10%
10%→10% share
▲1.0× share momentum24 median citations36% since 2021mostly empirical
Concerns are cooling (10%→10% of field), led by Immune system.
rising sub-themes (early→recent)
- Immune system2→5
- Virology2→3
- Nanotechnology2→3
Newly emergingChimeric antigen receptor 0→3 · Carbon nanotube 0→3
Landmark Nucleic Acid Delivery: The Missing Pieces of the Puzzle? · 350 cites
Common questions
How many Gene Therapy companies are there in California, United States?
Radar tracks 82 indexable Gene Therapy companies headquartered in California, United States that meet our profile-completeness bar.
What is the total funding raised by Gene Therapy companies in California, United States?
The Gene Therapy companies in California, United States on this list have raised a combined $3.7B in disclosed equity funding across 54 funded companies.
Which is the highest-funded Gene Therapy company in California, United States?
Kriya Therapeutics is the highest-funded Gene Therapy company in California, United States, with $617.6M in disclosed equity funding.
How many Gene Therapy companies in California, United States are funded?
54 of the 82 Gene Therapy companies in California, United States on this list have disclosed at least one equity funding round.
How many Gene Therapy unicorns are there in California, United States?
None of the Gene Therapy companies in California, United States on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in California, United States Gene Therapy companies?
The most active investors in California, United States Gene Therapy companies on this list include HHS, RA Capital Management, Foresite Capital, Versant Ventures, Alexandria.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.